Simon Waters

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 220 citations · Full text

The tetracycline resistance determinants of RP1 and Tn<i>l721</i>: nucleotide sequence analysis

Simon Waters, Peter Rogowsky, J. Grinsted et al. · Nucleic Acids Research · 1983 · 185 citations · Full text

Genetics, Molecular Biology, Molecular Genetics +17

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

Nicholas C. Turner, Claire Swift, Ben Jenkins et al. · Annals of Oncology · 2022 · 173 citations · Full text